Research & Development: Page 51
-
PharmaVoice Team/PharmaVoice
Implementing Interactive Response Technology in A Software-As-A-Service Model
Historically, the software used in clinical trials has taken the form of either a fully installed customized solution, or a hybrid customized and configurable solution. The implementation of such systems has been time-consuming with costly infrastructure, and because minimizing IT delivery times ...
By Jamey McCarty • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Clinical Trial Transformation Through Digital Clinical and Code Halos
What is “Digital Clinical?" As Morpheus tells Neo in the film The Matrix, “No one can be told what the Matrix is. You have to see it for yourself." Today we sometimes find ourselves immersed in our own real-life version of the Matrix, as our personal data accumulates on computer servers somewhere...
By Larry Florin • June 1, 2015 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
The Importance of A Beautiful Technology Experience
Do you remember when the first Apple iPod was released? The advertisements on television showed beautiful images of rotating color behind a clean silhouette dancing to the sounds coming from the earbuds. It was bold, fresh, and exciting. It was fun. We were not confused by technical specs. We wer...
By Ibraheem (IBS) Mahmood • June 1, 2015 -
PharmaVoice Team/PharmaVoice
How Do iComply? A Look at Regulatory Topics Surrounding the use of Mhealth Technology in Clinical Trials
The U.S. National Institutes of Health (NIH) Consensus Group has defined mHealth as “the use of mobile and wireless devices to improve health outcomes, health care services and health research." The mHealth landscape is expanding with over 97,000 apps (mobile applications) as of 2013. Yet the vas...
By Philip Coran • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Extracting Maximum Value From Electronic Data Capture
Electronic data capture (EDC) has been employed for clinical trial data for many years and is encouraged by the FDA because it provides significant benefits to sponsors, investigators, and patients, including more accurate data that can be more easily shared and monitored, increased compliance wi...
By Zaher El-Assi • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Which Patients Are Really at Risk For Becoming Non-Adherent?
If you’re targeting only the most obvious patients with your medication adherence programs, you’re missing out on a big opportunity. Quite often, outreach programs focus on individuals hovering around the 80% threshold for proportion of days covered (PDC). It makes sense. Why not use your resourc...
By Craig Schilling • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Seeing the Big Picture With Visual Data Analytics
Pharmaceutical and biotechnology companies are facing a gigantic increase in data — not just in volume, but in complexity. The number of clinical trials in the National Institute of Health’s registry has jumped from 5,635 in 2000 to 183,991 in 2015 — an increase of more than 30 times. The data la...
By Greg Moody • June 1, 2015 -
PharmaVoice Team/PharmaVoice
All Monitoring is Risk Based
Drug developers must introduce innovation across the entire life cycle of product development to more effectively bring new therapies to markets. The innovations will be recognized by the use of smarter and faster methods for discovery of new drug entities and companion diagnostics, use of flexib...
By Michael Brooks • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Managing the Scientific and Ethical Complexities of Medical Innovation
Today, advances in science and medicine are occurring at an unprecedented pace. These exciting changes broaden the ethical implications of medical innovation and expand the need to protect clinical research subjects. Often, Institutional Review Boards (IRBs) find themselves on the frontline of th...
By Lindsay McNair • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Maximizing Portfolio Value By Smart Partnering: This is Not Your Father's Oldsmobile
Portfolio value is traditionally associated with innovation value; i.e., intellectual property, market attractiveness, potential clinical utility, and other product-centric attributes. Less commonly considered is the differentiation afforded by the partnering process employed during clinical deve...
By Michael Murphy • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In this month’s Forum, experts from multiple disciplines, from drug development to marketing, discuss the challenges and opportunities that technology is bringing to the table. AstraZeneca’s CIO David Smoley sums up the changing landscape neatly: “When it comes to IT, we cannot operate in a world...
By Taren Grom • May 1, 2015 -
PharmaVoice Team/PharmaVoice
UpFront
Industry at Large AbbVie To Award 40 CF Scholarships AbbVie has announced the 2015 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now open to undergraduate and graduate students. For the 23rd year, the AbbVie CF Scholar...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Automating Medicinal Chemistry Through Building Blocks Martin Burke, M.D., Ph.D., and Mark Goldsmith, M.D., Ph.D., founded Revolution Medicines, which has an automated chemical synthesis platform that can be used to produce a broad range of molecules. Through the years of trial and error, researc...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
What's New
Turing Pharmaceuticals New Drug Company Launched Trending now: Experienced team comes together to focus on treating unmet medical needs. Turing Pharmaceuticals, a new pharmaceutical company, launched with news of three acquisitions for its commercial operations and development pipeline. New York-...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Cancer Care in America: A Shifting Landscape Trending now: Amid growing patient demand and administrative burden, there are stresses on the oncology care system. The U.S. cancer care system faces tremendous turbulence while dealing with growing numbers of cancer patients and survivors, mounting ...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
On the Calendar
Coming Attractions DIA 2015, the 51st annual meeting, is the largest multidisciplinary event that brings together a global network of life-sciences professionals to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. This year’s t...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biopharma Pool Steven Ertel Dr. Matthew Sherman Acceleron Pharma Announces Executive Appointments and Promotions Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Last Word
Enabling Cancer Immunotherapies Henry Li, Ph.D., VP, Translational Oncology at Crown Bioscience, talks about the challenges of developing new and novel cancer immunotherapeutics. PV: Cancer immunotherapy is a hot area of research now. Why do you think this is? Li: Cancer chemotherapies are toxic ...
By Henry Li • May 1, 2015 -
PharmaVoice Team/PharmaVoice
3D Applications in Medicine
Three-dimensional printing is no longer simple plastic prototypes. Today, 3-D printers can produce fully functional components, including complex mechanisms, batteries, transistors, and LEDs. 3D printing — also known as additive manufacturing — is the process of making three-dimensional solid obj...
By Denise Myshko • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Early Cancer Detection
For most cancers, diagnosis happens too late, when the cancer has worsened or metastasized. But when cancers are diagnosed early, survival statistics are much higher. For example, the five-year survival rate for patients diagnosed with colorectal cancer is around 90% if diagnosed when the cancer ...
By Denise Myshko • May 1, 2015 -
PharmaVoice Team/PharmaVoice
2015 HBA Luminaries
The Importance of Mentoring and Sponsorship Emily Lightfoot. AmerisourceBergen. Relationships with mentors have been the key to my career success. Having an advocate and coach to help me plan my career, discover my strengths, and identify opportunities has helped me develop confidence to take on ...
By Taren Grom • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Mary Thistle Dimension Names Chief Business Officer Dimension Therapeutics, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, has appointed Mary Thistle to the newly created position of chief bu...
By PharmaVoice Team • April 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A New Way to KILL INFECTIONS Mark Offerhaus, Chief Executive of the Dutch firm Micreos, talks about the company’s antibiotic alternative that uses endolysins. Antibiotic resistance is increasingly becoming a serious global threat to public health and is the cause of many common infections, includ...
By Mark Offerhaus • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Putting the “e" in Patient-Reported Outcomes Trending now: Electronic data collection improves data quality, shortens study timelines, and increases the likelihood of regulatory approval. Although transitioning from a pen-and-paper strategy to an electronic patient-reported outcome (ePRO) approac...
By PharmaVoice Team • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Tony Hunt Repligen Names CEO Repligen, a life-sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs, has appointed Tony Hunt as CEO. Mr. Hunt, currently Repligen’s chief operatin...
By PharmaVoice Team • March 1, 2015
Previous
